Early Childhood Onset Retinal Dystrophy

Severe Early Childhood Onset Retinal Dystrophy (SECORD) is a rare, inherited eye condition that causes severe vision loss beginning in early childhood, usually before a child turns 5 years old. It is closely related to another condition called Leber Congenital Amaurosis (LCA), but children with SECORD often have slightly better vision in their early years. The condition primarily affects the retina, the light-sensitive tissue at the back of the eye, leading to symptoms like severe night blindness, involuntary eye movements (nystagmus), and a progressive decline in overall vision. Patients and their families should know that SECORD is a progressive disease, meaning vision will gradually worsen over time. While some children may maintain useful vision into their teens, many individuals with SECORD become legally blind by the time they reach their 30s. Because it is a genetic condition, it is passed down from parents who are typically carriers of the mutated gene but do not have the disease themselves. Genetic testing is very important for families, as it can confirm the diagnosis and help determine if the patient might be a candidate for new, targeted treatments, such as gene therapy, which are currently being developed and tested for specific genetic forms of the disease.

Condition category: Retinal Dystrophy

Prevalence: 1 in 33,000 to 1 in 81,000 (grouped with LCA)

Inheritance patterns: Autosomal Recessive

Age of onset: Birth to early childhood

Clinical overview: Severe Early Childhood Onset Retinal Dystrophy (SECORD) is a severe, recessively inherited retinal dystrophy that falls within the spectrum of early-onset retinal dystrophies, closely related to Leber Congenital Amaurosis (LCA). It is clinically defined by presentation after infancy but typically before the age of 5 years. SECORD is characterized by severe congenital night blindness, progressive retinal dystrophy, nystagmus, and poor pupillary light responses. While it shares significant genetic and phenotypic overlap with LCA, SECORD is generally distinguished by better residual visual function in early childhood and the presence of small, detectable signals on full-field electroretinogram (ERG), particularly for the lesser-affected photoreceptor system. The clinical features of SECORD can vary depending on the specific genetic etiology. Fundus examination may initially be normal but progressively develops abnormalities such as peripheral pigmentary retinopathy, vessel attenuation, disc pallor, and macular changes. Specific genotypes may present with characteristic phenotypes; for example, RDH12-associated disease often features early-dense intraretinal pigment migration and maculopathy, while RPE65-associated disease may show a blonde fundus with peripheral white punctate lesions. Optical coherence tomography (OCT) can reveal varying degrees of outer retinal preservation or loss, which is crucial for assessing the potential for therapeutic interventions. SECORD is genetically heterogeneous, with mutations in genes such as RPE65, LRAT, and RDH12 being commonly implicated. These genes are primarily involved in the visual cycle and photoreceptor maintenance. The progressive nature of the disease leads to significant visual impairment, with best-corrected visual acuity potentially reaching 0.3 in the first decade but often progressing to complete blindness by the third decade of life. Accurate diagnosis relies on a combination of clinical evaluation, electrophysiology, and molecular genetic testing, which is essential for guiding management and determining eligibility for emerging gene therapies.

Patient and family guide: Severe Early Childhood Onset Retinal Dystrophy (SECORD) is a rare, inherited eye condition that causes severe vision loss beginning in early childhood, usually before a child turns 5 years old. It is closely related to another condition called Leber Congenital Amaurosis (LCA), but children with SECORD often have slightly better vision in their early years. The condition primarily affects the retina, the light-sensitive tissue at the back of the eye, leading to symptoms like severe night blindness, involuntary eye movements (nystagmus), and a progressive decline in overall vision. Patients and their families should know that SECORD is a progressive disease, meaning vision will gradually worsen over time. While some children may maintain useful vision into their teens, many individuals with SECORD become legally blind by the time they reach their 30s. Because it is a genetic condition, it is passed down from parents who are typically carriers of the mutated gene but do not have the disease themselves. Genetic testing is very important for families, as it can confirm the diagnosis and help determine if the patient might be a candidate for new, targeted treatments, such as gene therapy, which are currently being developed and tested for specific genetic forms of the disease.

Symptoms and clinical features: Symptoms of Severe Early Childhood Onset Retinal Dystrophy (SECORD) typically begin to appear in early childhood, usually between infancy and 5 years of age. The hallmark symptom is severe congenital night blindness, making it extremely difficult for the child to see in low-light conditions. Other early signs include nystagmus (involuntary, rapid eye movements) and poor pupillary responses to light. Children may also exhibit the "oculodigital sign," which involves frequent poking or rubbing of the eyes. As the disease progresses, individuals experience a gradual decline in visual acuity and a constriction of their visual field. While some useful vision may be retained into the second decade of life, the vision loss is progressive and often leads to complete blindness by the age of 30. The severity and specific progression of symptoms can vary depending on the underlying genetic mutation.

Molecular pathology: Severe Early Childhood Onset Retinal Dystrophy (SECORD) is a genetically heterogeneous condition caused by mutations in several genes that are crucial for retinal function and maintenance. The most commonly associated genes include RPE65, LRAT, and RDH12. These genes encode proteins that play vital roles in the visual cycle, phototransduction, and photoreceptor development and integrity. For instance, the RPE65 gene encodes a retinoid isomerohydrolase expressed in the retinal pigment epithelium (RPE), which is essential for the regeneration of 11-cis-retinol in the visual cycle. Mutations in RPE65 lead to a deficiency in 11-cis-retinal, resulting in the inability of photoreceptors to respond to light and subsequent photoreceptor degeneration. Similarly, the LRAT gene encodes lecithin retinol acyltransferase, another key enzyme in the visual cycle responsible for esterifying all-trans-retinol. Mutations in LRAT disrupt the visual cycle, leading to visual impairment. The RDH12 gene encodes retinol dehydrogenase 12, an enzyme involved in the reduction of all-trans-retinal to all-trans-retinol. Mutations in RDH12 cause early-onset severe retinal dystrophy characterized by dense intraretinal pigmentation and macular atrophy. The molecular mechanisms underlying SECORD generally involve the disruption of these critical biochemical pathways, leading to the accumulation of toxic byproducts, such as lipofuscin, and the progressive death of photoreceptor cells, ultimately resulting in severe vision loss.

Genetics: Severe Early Childhood Onset Retinal Dystrophy (SECORD) is primarily inherited in an autosomal recessive pattern. This means that an affected individual must inherit two copies of the mutated gene, one from each biological parent. Parents of an affected child are typically carriers, possessing one mutated copy and one normal copy of the gene, and generally do not exhibit symptoms of the disease. When both parents are carriers, there is a 25% chance with each pregnancy of having an affected child, a 50% chance of having a child who is a carrier, and a 25% chance of having a child who inherits two normal copies of the gene. The condition exhibits high penetrance, meaning that individuals with two pathogenic variants will almost certainly develop the disease. However, expressivity can vary, with differences in the rate of progression and severity of visual impairment even among individuals with the same genetic mutation. Genetic counseling is highly recommended for affected individuals and their families to discuss the inheritance pattern, risks to future offspring, and the availability of carrier testing for at-risk relatives. Identifying the specific genetic mutation through molecular testing is crucial for accurate counseling and potential eligibility for gene-specific therapies.

Diagnostic evaluation: Diagnosis of Severe Early Childhood Onset Retinal Dystrophy (SECORD) is established through a combination of clinical examination, electrophysiology, and genetic testing. Clinical evaluation typically reveals severe visual impairment, nystagmus, and poor pupillary light responses. Fundus examination may initially appear normal but progresses to show peripheral pigmentary retinopathy, vessel attenuation, and macular abnormalities. Full-field electroretinogram (ERG) is a critical diagnostic tool, showing severely abnormal or undetectable responses, with small residual signals often present for the lesser-affected photoreceptor system. Molecular genetic testing is essential to confirm the diagnosis and identify specific pathogenic variants in genes such as RPE65, LRAT, or RDH12. Optical coherence tomography (OCT) may be used to assess retinal structure, revealing varying degrees of outer retinal preservation or loss depending on the specific genotype.

Differential diagnosis: Leber Congenital Amaurosis, Achromatopsia, S-cone monochromatism, Congenital stationary night blindness, Albinism, Retinitis Pigmentosa

Natural history: The natural history of Severe Early Childhood Onset Retinal Dystrophy (SECORD) is characterized by early and progressive visual impairment. Symptoms typically present after infancy but before the age of 5 years. Initial signs often include severe congenital night blindness, nystagmus, and poor pupillary light responses. Unlike Leber Congenital Amaurosis (LCA), which presents at birth or within the first few months of life, children with SECORD may have better residual visual function initially. Best corrected visual acuity can reach 0.3 in the first decade of life and may be maintained into the second decade. However, the disease is progressive, leading to a gradual decline in visual acuity and visual field constriction. By the age of 30 years, blindness is often complete. The rate of progression and specific clinical features can vary depending on the underlying genetic mutation.

Management and treatment research: ### Current management and support Early childhood onset retinal dystrophy is managed by addressing each child’s visual needs and supporting development. The condition can result from changes in many different genes, and severity and progression vary widely. - **Regular eye care:** Follow-up with a pediatric ophthalmologist and, when available, an inherited retinal disease specialist can monitor vision, retinal changes, refractive errors (such as farsightedness or nearsightedness), strabismus, cataracts, and other eye conditions that may be treatable. - **Low-vision services:** Glasses, magnifiers, electronic visual aids, contrast-enhancing tools, large-print materials, and other assistive technology may help children use their remaining vision effectively. - **Early intervention and educational support:** Vision-specific early-intervention services, orientation and mobility training, classroom accommodations, braille or accessible-format instruction when needed, and individualized education planning can support learning and independence. - **Developmental and family support:** Occupational therapy, developmental specialists, social work, and genetic counseling may help address developmental needs, connect families with services, and explain inheritance patterns. - **Genetic testing:** Identifying the gene responsible for the retinal dystrophy can clarify the diagnosis, inform family planning, and determine whether gene-specific treatment or research opportunities may be relevant. ### Approved therapies There is no treatment approved specifically for early childhood onset retinal dystrophy as a broad diagnostic category. Treatment eligibility depends on the underlying genetic cause. For people with confirmed **biallelic *RPE65*-associated retinal dystrophy**, which can present in early childhood, **voretigene neparvovec-rzyl (Luxturna)** is an approved retinal gene therapy in the United States. It is given by subretinal injection and delivers a functional copy of the *RPE65* gene to retinal cells. Eligibility requires genetic confirmation and sufficient remaining viable retinal cells, as determined by a retinal specialist. ### Investigational therapies There are currently no condition-specific investigational treatment programs listed in the available pipeline data for early childhood onset retinal dystrophy. Research across inherited retinal diseases includes gene-based treatments, medicines intended to protect retinal cells or affect disease pathways, and other approaches. Whether a person may qualify for a study depends on the specific genetic diagnosis, age, retinal structure, vision level, and other study criteria. ### Clinical trial participation One recruiting natural-history and patient registry study may be relevant for some individuals with inherited retinal disease: - **NCT01793168 — Rare Disease Patient Registry & Natural History Study – Coordination of Rare Diseases at Sanford.** This recruiting study, sponsored by Sanford Health, collects health and disease-course information to improve understanding of rare conditions and support future research. Natural-history studies do not test a new treatment. However, participation may help researchers understand how conditions change over time and may help families stay connected with research opportunities. Genetic testing and discussion with an inherited retinal disease specialist can help identify studies that may be appropriate.

Outlook: The prognosis for individuals with Severe Early Childhood Onset Retinal Dystrophy (SECORD) involves progressive and severe visual impairment. While children may retain some useful vision (best corrected visual acuity up to 0.3) during their first and second decades of life, the condition typically leads to complete blindness by the age of 30. The severe vision loss significantly impacts quality of life, requiring early educational and developmental support, including mobility training and adaptive technologies, to help individuals navigate daily activities and maintain independence.

Epidemiology: Severe Early Childhood Onset Retinal Dystrophy (SECORD) is a rare inherited retinal disease. While specific prevalence data for SECORD alone is limited, it is often grouped with Leber Congenital Amaurosis (LCA). Together, LCA and SECORD have an estimated prevalence ranging from 1 in 33,000 to 1 in 81,000 individuals. These conditions account for approximately 5% or more of all inherited retinal diseases. SECORD typically presents in early childhood, usually before the age of 5 years, and affects individuals across various demographics without a known specific ethnic predilection, though consanguinity can increase the risk in certain populations.

Selected references: 1. Kumaran N, Moore AT, Weleber RG, Michaelides M. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. Br J Ophthalmol. 2017;101(9):1147-1154. 2. National Institutes of Health. Severe early-childhood-onset retinal dystrophy. Genetic and Rare Diseases Information Center. 3. Sergouniotis PI, Davidson AE, Mackay DS, et al. The phenotype of Severe Early Childhood Onset Retinal Dystrophy (SECORD) caused by mutations in the RPE65 gene. Invest Ophthalmol Vis Sci. 2011;52(1):212-218.